|
Senate Bill
|
644
|
An Act relative to consumer deductibles
|
Support
|
$0.00
|
n/a
|
|
Senate Bill
|
2774
|
The Governor’s Health Care Proposal: An Act investing in the future of our health; specifically sections 6, 11, 14, 20 and 26 (New Chapter 63E).
|
Oppose
|
$5,000.00
|
n/a
|
|
House Bill
|
1237
|
An Act relative to non-medical switching
|
Support
|
$0.00
|
n/a
|
|
House Bill
|
1053
|
An Act relative to consumer deductibles
|
Support
|
$14,000.00
|
n/a
|
|
Senate Bill
|
756
|
An Act relative to step therapy and patient safety
|
Support
|
$0.00
|
n/a
|
|
House Bill
|
385
|
extending co-pay assistance law out to the year 2026
|
Support
|
$0.00
|
n/a
|
|
Senate Bill
|
771
|
An Act relative to pharmaceutical access, costs and transparency
|
Oppose
|
$0.00
|
n/a
|
|
Senate Bill
|
644
|
An Act relative to consumer deductibles
|
Support
|
$0.00
|
n/a
|
|
House Bill
|
1278
|
An Act relative to prescription drug price transparency
|
Oppose
|
$0.00
|
n/a
|
|
House Bill
|
1137
|
An Act relative to cancer patient access to biomarker testing to provide appropriate therapy
|
Support
|
$0.00
|
n/a
|
|
Senate Bill
|
1481
|
An Act to restore integrity in the marketing of pharmaceutical products and medical devices
|
Oppose
|
$0.00
|
n/a
|
|
Executive
|
Massachusetts Health Policy Commission (HPC)
|
Discussed workforce development in the wake of COVID-19 with the Health Policy Commission. Continued discussions with members of the Executive and Legislative branches concerning the development and potential rollout of AstraZeneca’s COVID-19 vaccine and AstraZeneca’s monoclonal antibody Evusheld. As of the filing of this report, AstraZeneca’s vaccine has yet to be approved by the Food & Drug Administration (FDA). Thus, these discussions were for planning purposes only in the event the vaccine was approved. The ongoing discussions on the awareness and access to Evusheld were in response to distribution via the federal government to the Commonwealth of MA after receiving emergency use authorization from the FDA. Specifically on COVID vaccine, members of the Legislative House COVID-19 Working Group. These topics pertained to the progress of clinical trials, distribution, and supply. Engaged on various COVID-19 current Executive Orders to ensure compliance with our essential laboratory wo
|
Neutral
|
$6,000.00
|
n/a
|
|
House Bill
|
1311
|
An Act relative to step therapy and patient safety
|
Support
|
$0.00
|
n/a
|
|
House Bill
|
1053
|
An Act relative to consumer deductibles
|
Support
|
$0.00
|
n/a
|
|
House Bill
|
1254
|
An Act relative to promoting comprehensive transparency in the pharmaceutical industry
|
Oppose
|
$0.00
|
n/a
|
|
Senate Bill
|
580
|
repealing the sunset on co-pay assistance law
|
Support
|
$0.00
|
n/a
|
|
House Bill
|
729
|
An Act to ensure prescription drug cost transparency and affordability
|
Oppose
|
$0.00
|
n/a
|
|
Senate Bill
|
831
|
extending co-pay assistance law out to the year 2026
|
Support
|
$0.00
|
n/a
|
|
Senate Bill
|
2651
|
An Act relative to pharmaceutical access, costs and transparency
|
Oppose
|
$0.00
|
n/a
|
|
House Bill
|
1224
|
An Act relative to promoting healthcare access and affordability for patients
|
Support
|
$0.00
|
n/a
|
|
Executive
|
Massachusetts Health Policy Commission (HPC)
|
Engaged in discussions related to indirect & direct price controls of prescription drugs. Engaged in the Health Policy Commission (HPC) Drug Pricing Review Process to include public comment and the Standard Reporting Form. Specifically the process for determining valuation of Rx drugs, transparency reporting requirements and rebate negotiations. Member of the HPC Advisory Council and participated virtually on their 2 quarterly meetings in the first half of the year.
|
Oppose
|
$3,000.00
|
N/A
|
|
House Bill
|
1191
|
An Act to help patients and reduce health care costs by ensuring patient adherence to medications
|
Support
|
$0.00
|
n/a
|
|
Senate Bill
|
808
|
An Act relative to cancer patient access to biomarker testing to provide appropriate therapy
|
Support
|
$0.00
|
n/a
|
|
Senate Bill
|
1184
|
Senate Budget section related to Direct Negotiations for certain drugs and non-drug products. Amendment 1184 to H4700 related to Drug Coupon Study Task Force
|
Neutral
|
$1,000.00
|
n/a
|
|
House Bill
|
1201
|
An Act ensuring access to medications
|
Support
|
$0.00
|
n/a
|
|
House Bill
|
4262
|
An Act Enhancing the Market Review Process.
|
Neutral
|
$0.00
|
n/a
|
|
Executive
|
Attorney General's Office (AGO)
|
Engaged with the Office of the Attorney General regarding a matter related to the use of electronic vouchers (eVouchers) for one of our prescription drug products. The matter pertains to the use of eVouchers in the presence of an available generic product as it relates to the existing Co-Pay Assistance statute. I engaged the AG’s office in order to get assistance with an interpretation of how the law applies to this specific market availability of a related generic product. Had multiple discussions with various stakeholders on promoting the potential for biomarker testing coverage and prior authorization procedures (separate from specific legislation). We have our introduced biomarker bill listed below but these were amplifying discussions that would edit our bill language. Promoted and assisted with information pertaining to the HPC study on the use of prescription drug coupons and vouchers. Interactions (virtual) with the HPC and participation in the HPC Advisory Council quarterly me
|
Support
|
$10,000.00
|
N/A
|
|
Senate Bill
|
696
|
An Act to help patients and reduce healthcare costs by ensuring patient adherence to medications
|
Support
|
$0.00
|
n/a
|
|
Senate Bill
|
627
|
An Act relative to promoting healthcare access and affordability for patients
|
Support
|
$0.00
|
n/a
|
| | | |
Total amount
|
$39,000.00
| |